Sponsor Deadline
Posted: 3/3/2022

NCCN, Pfizer and Myovant Quality Improvement Initiative: Understanding and Mitigating Cardiovascular Risk in Patients with Prostate Cancer

The  National  Comprehensive Cancer  Network®  (NCCN),  Pfizer  Global  Medical  Grants  (Pfizer)  and Myovant  Sciences  (Myovant)  are  collaborating  to  offer  a  new  grant  opportunity  seeking  proposals  to improve the  cardiovascular  management  of  patients  with prostate  cancer  being  treated with androgen deprivation therapy  (ADT).

Roughly  half  of  the men treated  for  prostate cancer  receive  ADT,  often for  a  prolonged  duration.  The majority  of  these  men have pre-existing  risk  factors  for  cardiovascular  disease,  which  is  the  primary cause of  non-cancer  death among  men with prostate cancer.  There is  a  well-documented  association between castration or  low  testosterone levels  and cardiovascular  morbidity.  Androgen deprivation therapies can increase the risk of cardiovascular disease both by testosterone suppression itself (which is associated with dyslipidemia, metabolic syndrome, and vascular effects) and potentially by the mechanism of testosterone suppression (i.e. alterations in FSH and the immune system by GnRH agonists). Recent evidence suggests that intensive management of cardiovascular disease during ADT can reduce the incidence of major adverse cardiovascular events. Contemporary data also shows that roughly a third of men with uncontrolled risk factors for cardiovascular events are not on appropriate medications and that there is a high burden of modifiable cardiovascular risk factors among men with prostate cancer. The relative contribution of the various forms of androgen deprivation (i.e. GnRH agonists or GnRH antagonists) and/or the suboptimal management of cardiovascular risk factors is not known. 

 Potential strategies to limit cardiovascular morbidity in men with prostate cancer include improving awareness and identification of, and implementation of interventions for known modifiable risk factors (i.e. hypertension, dyslipidemia, diabetes) for cardiovascular disease. Further approaches may include those that could limit the duration of testosterone suppression for men with prostate cancer. Finally, an increased understanding of the influence of androgen deprivation therapy on the cardiovascular system and how therapy can affect men of different genetic and ancestral backgrounds may improve individualized management. This request for proposals seeks to solicit projects that focus on the improvement of the cardiovascular health for men with prostate cancer, particularly those treated with ADT.  

Proposal Submission Deadline: Tuesday, April 26, 2022

Eligibility Requirements

Geographic Scope: United States

• NCCN Member Institutions.  • Collaboration between NCCN Member Institutions is strongly encouraged in order to foster the interactive sharing of knowledge and expertise, and to utilize the combined clinical strengths of members, particularly in the case of uncommon tumors. Although the submitting investigator must be from an NCCN Member Institution, participating co-investigators do not need to be at an NCCN Member Institution. This can also include cross-institutional collaboration for the conduct of correlative studies. • Proposal submissions from Junior Faculty are encouraged. • Trainees may participate as a sub-investigator under the appropriate mentorship from a PI from a NCCN Member Institution. 

Amount Description

• There is $1.5 Million available for funding of all projects. • Study drug(s) will not be provided. • The intent is to fund individual projects capped at $250,000 (direct and indirect costs) although smaller, lower-costs projects are encouraged. Funding greater than $250,000 will be considered for exceptional proposals with detailed budget justification. • The maximum indirect (overhead) rate is 25% and must be included in the total grant request amount. • Applicants are required to disclose additional sources of funding for this project and demonstrate that funding does not overlap. • The decision relative to funding is deferred to the members of the Scientific Review Committee (SRC) as chosen by NCCN and independent of Pfizer and Myovant.   

Funding Type